With every passing day, the GLP-1 story in India seems like a character test. Every structural condition for a super-cycle exists in the opportunity. We have between 101 million to 212 million diabetics, a March 2026 patent expiry on semaglutide, a 34% CAGR domestic anti-obesity market, and oral formulations about to eliminate the cold chain barrier entirely. What is missing is not capital, not manufacturing capability, not distribution reach. What is missing is the willingness to hold an ambition the size of the opportunity.
The Indian generic industry’s response has been to file generics, supply APIs, and distribute for MNCs. While this is not wrong, it is just small. As I said before, the durable GLP-1 opportunity is not in the molecule, it is in owning the metabolic patient via adherence platforms, chronic care pathways, disease management built around a decade-long relationship.
Meanwhile, Hengrui is in Phase 3 with a next-generation dual agonist showing 18% weight loss. Innovent got a novel GCG/GLP-1 molecule approved in China last year, the world's first. One-third of all global pharma licensing deal spending in H1 2025 involved Chinese-origin drugs. China is not waiting for the patent cliff. China is building the next one.
I spoke to senior people inside Indian pharma companies who track this market closely. What I found wasn't strategic disagreement. It was vertigo. The scale of the GLP-1 category disorients them before they have even begun to act. That is not a capital problem but an imagination problem. Which is why the dominant strategic posture of Indian generic pharma is to file, manufacture, and wait for the price war.
Listen in!
